|
|
Vaccine Detail
|
Autologous Dinitrophenyl Vaccine |
| Vaccine Information |
- Vaccine Name: Autologous Dinitrophenyl Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007290
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Preparation: The vaccine consisted of autologous tumor cells modified with the hapten, dinitrophenyl, mixed with bacille Calmette-Guérin (Berd et al., 2004).
- Description: A vaccine consisting of autologous cancer cells modified with the hapten, Dinitrophenyl. The treatment program consists of multiple intradermal injections of irradiated DNP-modified autologous tumor cells mixed with bacillus Calmette-Guerin. (NCIT_C1982).
This vaccine have been research involving melanoma. (Sato et al., 1997)
|
| Host Response |
|
|
| References |
Berd et al., 2004: Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(3); 403-415. [PubMed: 14691123].
NCIT_C1982: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1982]
Sato et al., 1997: Sato T, Bullock TN, Eisenlohr LC, Mastrangelo MJ, Berd D. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides. Clinical immunology and immunopathology. 1997; 85(3); 265-272. [PubMed: 9400626].
|
|
